FAILED TRIAL: Ph 2 NuTide:323 CRC Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee September 3, 2024
First Solid Tumor Patient Treated with Second, Higher Dose in Ph 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease August 27, 2024
Positive Topline Results from Tafasitamab (Monjuvi®) trial in R/R Follicular Lymphoma Announced August 22, 2024
Ph 2 results from LTX-315 skin cancer (BCC) trial show an 86% overall reduction of tumor size, complete clearance in half of the patients August 22, 2024
Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from Ph 2 SPARTA Trial Announced August 22, 2024
Sarclisa induction treatment demonstrated significantly improved PFS in patients with newly diagnosed multiple myeloma eligible for transplant August 13, 2024
FAILED TRIAL: FOCUS Ph II Trial of UV1 + Pembrolizumab didn’t improve PFS & OS in Patients with Metastatic or Recurrent Head and Neck Cancer August 13, 2024
Initial Data from Ph 1 Clinical Trial of EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 announced August 13, 2024
Fixed-duration Calquence + venetoclax, with or without obinutuzumab, significantly improved PFS in 1L CLL in AMPLIFY Ph 3 trial August 7, 2024
Topline Data From ASPEN-06 Ph 2 Trial shows Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer August 7, 2024
Positive Topline Ph 2 Results Announced for mRNA Immunotherapy BNT111 in Patients with Advanced Melanoma August 6, 2024
11.1 Month Increase in OS in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 in OVATION 2 Ph 2 trial Announced August 6, 2024
FAILED TRIAL: Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies show primary endpoint of OS improvement not achieved August 6, 2024
Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved PFS in 1L CLL in AMPLIFY Ph 3 trial July 30, 2024
Positive treatment updates announced from Ph 2 clinical trial, THIO-101, of THIO + cemiplimab (Libtayo®) in heavily pre-treated patients with advanced NSCLC July 30, 2024
Darolutamide meets primary endpoint in Ph 3 ARANOTE trial in men with metastatic hormone-sensitive prostate cancer July 23, 2024
FAILED TRIAL: Ph 3 TiNivo-2 didn’t meet primary endpoint from rechallenging RCC patients with immunotherapy after receiving ICI beyond progression on previous ICIs July 23, 2024
Positive Interim Ph 2 Monotherapy Expansion Data for IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced July 17, 2024
Safety Approval Announced for the First Dose Cohort in Ph 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors July 17, 2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma July 17, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in OS in landmark CARTITUDE-4 study July 9, 2024
FAILED TRIAL: Ph 2/3 SKYSCRAPER-06 trial of tiragolumab, Tecentriq and chemo did not meet the primary endpoints of PFS at primary analysis and OS at first interim analysis July 9, 2024
